 |
|
|
| |
Novel Imaging Strategy Shows High-Level Aortic CD206+
Macrophage Infiltration in HIV ......CVD risk / inflammation
|
| |
| |
"We performed a first-in-human investigation testing whether systemic administration of 99mTc-tilmanocept (which specifically binds CD206+ macrophages) would enable quantification of arterial macrophage infiltration.....to evaluate presence of Systemic monocyte activation and arterial macrophage infiltration thought to contribute to heightened cardiovascular disease risk in HIV and to quantify macrophage-specific arterial inflammation."
"Among HIV-infected subjects, duration since HIV diagnosis was 23.3 ± 8.1 years, log10 VL was 1.4 (1.3, 2.8) copies/mL, and CD4 count was 534 ± 138 cells/mm3 .
High-level 99mTc-tilmanocept uptake.... was apparent across 20.4% of the aortic surface volume in HIV-infected subjects versus 4.3% in non-HIV-infected subjects (P=0.009) (Figure 2)."
"Representative 99mTc-tilmanocept SPECT/CTs demonstrating high-level tilmanocept uptake in (a) HIV-infected and (b) non-HIV-infected subjects with similar Framingham Risk Scores and subclinical atherosclerosis"
"Aortic volume with high-level tilmanocept uptake correlated significantly with non-calcified aortic plaque volume on CT angiography."
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
Markella V. Zanni, M.D. *, Mabel Toribio, M.D., * Moses Q. Wilks, Ph.D. , Michael T. Lu, M.D., , Tricia H. Burdo, Ph.D., Fred Cope, Ph.D., Udo Hoffmann, M.D., Kenneth C. Williams, Ph.D., Georges El-Fakhri, Ph. D., Steven K. Grinspoon, M.D.
|
| |
|
|
|
|
|
